Get started
Novo is still in an ascending trendMy post is primarily a technical analysis. It is important you understand a technical analysis is a forecast and has a probability, and not a statement that it will be absolutely certain. Fundamental analysts (25) have on Trading View a price target of 1020. There is a wide spread, but most are positive about the stock. Novo is still in an ascending trend as evidenced by the price movements and the moving averages. The price has broken through the resistance at 966, where there is support now. There are two REC, where the big one has an object about 1050 and the small an object about 1030. There is a poor correlation between price peaks and volume peaks. This weakens the trend. RSI just over 50. RSI and OBV do not go up as the price from the beginning of February. From mid-February, the price has divergences to the stochastic oscillator %D. The sum of oscillators and moving averages is from one day to a month on purchase. Considering the stock technically positive for a medium length of time, one to 6 months. Disclaimer: I hold a position in the stock. Remember you need do your own research and assessment before buying and selling. Sources: Trading View
OMXCOP:NOVO_B
by scorpiris
2
Royal Unibrew The stock is in a declining trend channel. It appears scroll. of the long moving averages and charts. Looking back, there will be a support around 480 (5 year chart). RSI 21 and OBV have gone up and then flattened out somewhat when you look at the last 40 days. The last week some hammer candlestick pointing down. MA and oscillators stand one month on neutral. The price has been in a flat development for a little month and a clear movement up or down from here will give direction at least in the short term. Consider the stock technically weak negative in the medium term. This is a technical analysis, but fundamental analysts are preferably positive about the stock. Remember you need do your own research and assessment before buying and selling. Disclaimer: I hold a position in the stock. Sources: Trading View
OMXCOP:RBREW
by scorpiris
A defensive stock in a rising trend Measured by value, Novo Nordisk is Northern Europe's largest business and headquartered in Bagsværd, Denmark. It's a defensive stock that's done well. It is considered a bit of a weakness that they have the majority of their income on few products, but on the other hand they are good at what they are doing. There are some medicine companies that have spread too much and have had to give up some of what they have been doing. This link provides a very good insight into the issue around Q2. It's in Danish. app.marketingplatform.com Price target: Trading View a year 860. Handelsbanken SE 3 years 925. Danske Bank 900. This chart is YTD, but the trend lines are drawn after a longer chart 1Y. Novo Nordisk is on a rising trend as evidenced by MA. Volume supports the trend as price top respond to volume top and price bottom respond to volume bottom. On volume balance OVB rising 22 days back. There was a dive after Q2 on August 4th, but the next day there are more people buying in than selling out on the first day. RSI 21 slightly below 50. Oscillators and MA stand on sell one day, neutral a week and buy a month. Considers the stock technically positive for medium long time. Disclaimer: I have a position in the stock. Remember you need do your own research and assessment before buying and selling. Sources: Trading View.
OMXCOP:NOVO_B
by scorpiris
BAVA MonkeyPox VaccineHere we go again...? "The spread of monkeypox boosted the shares of Bavarian Nordic A/S, which says it’s the only company to make a vaccine approved for the viral infection. The Danish company gained as much as 26% in Copenhagen trading on Thursday after saying it had secured a contract to supply its smallpox shot -- which is also cleared against monkeypox -- to an undisclosed European country. Monkeypox, a virus that is endemic in some forested parts of central and west Africa, has been found in a handful of cases in the UK, Spain and Portugal in recent days and in one person in the US. The World Health Organization said Wednesday it was monitoring a situation that 'is evolving rapidly.' " www.bloomberg.com
OMXCOP:BAVALong
by reiiss7